Russian Direct Investment Fund is Russia’s sovereign wealth fund created in 2011 to make equity co‑investments in Russian companies alongside international investors; it is an investment vehicle, not a drug developer, and therefore has no therapeutic pipeline or clinical-stage assets of its own.[2][3][5][9][10]
Industry
Investors
02
Partnerships
China Investment Corporation – Russian-Chinese Investment Fund[2]Rönesans Holding – joint investments including healthcare and infrastructure[2]Various international sovereign and institutional co‑investors from more than 18 countries with over $40 billion committed alongside RDIF[2][5][10][12]Digital Medical Services (Rostelecom/RT Labs, Rostec) and Doctis – joint telemedicine platform with MD Medical Group[4]Multiple COVID‑19–related partners through promotion and financing of Gamaleya Institute vaccines and other healthcare collaborations in China, Cuba, India and other countries[6][8][11][12]
Beyond the preview
Go deeper on Russian Direct Investment Fund.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Russian Direct Investment Fund.